Abstract:BACKGROUND:Breast cancer (BC) is the most commonly diagnosed cancer. Currently, mammography and breast ultrasonography are the main clinical screening methods for BC. Our study aimed to reveal the specific metabolic profiles of BC patients and explore the specific metabolic signatures in human plasma for BC diagnosis.METHODS:This study enrolled 216 participants, including BC patients, benign patients, and healthy controls (HC) and formed two cohorts, one training cohort and one testing cohort. Plasma samples were collected from each participant and subjected to perform nontargeted metabolomics and proteomics. The metabolic signatures for BC diagnosis were identified through machine learning.RESULTS:Metabolomics analysis revealed that BC patients showed a significant change of metabolic profiles compared to HC individuals. The alanine, aspartate and glutamate pathways, glutamine and glutamate metabolic pathways, and arginine biosynthesis pathways were the critical biological metabolic pathways in BC. Proteomics identified 29 upregulated and 2 downregulated proteins in BC. Our integrative analysis found that aspartate aminotransferase (GOT1), L-lactate dehydrogenase B chain (LDHB), glutathione synthetase (GSS), and glutathione peroxidase 3 (GPX3) were closely involved in these metabolic pathways. Support vector machine (SVM) demonstrated a predictive model with 47 metabolites, and this model achieved a high accuracy in BC prediction (AUC = 1). Besides, this panel of metabolites also showed a fairly high predictive power in the testing cohort between BC vs HC (AUC = 0.794), and benign vs HC (AUC = 0.879).CONCLUSIONS:This study uncovered specific changes in the metabolic and proteomic profiling of breast cancer patients and identified a panel of 47 plasma metabolites, including sphingomyelins, glutamate, and cysteine could be potential diagnostic biomarkers for breast cancer.

Mass Spectrometry (LC–MS/MS) Identified Proteomic Biosignatures of Breast Cancer in Proximal Fluid

Integrative Analysis of Plasma Metabolomics and Proteomics Reveals the Metabolic Landscape of Breast Cancer

Breast cancer plasma protein biomarker discovery by coupling LC-MS/MS proteomics and systems biology

Breast Cancer-Specific Serum Peptide Profiles

A Proteomics Platform Combining Depletion, Multi-Lectin Affinity Chromatography (M-Lac), and Isoelectric Focusing to Study the Breast Cancer Proteome

Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers.

Comparative serum proteome analysis of human lymph node negative/positive invasive ductal carcinoma of the breast and benign breast disease controls via label-free semiquantitative shotgun technology.

Mass Spectrometry-Based Quantitative Metabolomics Revealed A Distinct Lipid Profile In Breast Cancer Patients

Relative Quantification of Proteins in Formalin-Fixed Paraffin-Embedded Breast Cancer Tissue Using Multiplexed Mass Spectrometry Assays

Detection and identification of potential biomarkers of breast cancer

Dual-function Biomarkers for Detection of Breast Cancer and Its Cancer Type: Invasive Versus Non-Invasive.

The Analysis of Plasma Proteomics for Luminal A Breast Cancer

Use of Serological Proteomic Methods to Find Biomarkers Associated with Breast Cancer

Mass Spectrometry-Based Proteomics of Human Milk to Identify Differentially Expressed Proteins in Women with Breast Cancer versus Controls

Quantitative tissue proteomic investigation of invasive ductal carcinoma of breast with luminal B HER2 positive and HER2 enriched subtypes towards potential diagnostic and therapeutic biomarkers

Evaluation of a Proteomics-Guided Protein Signature for Breast Cancer Detection in Breast Tissue

Identification of Breast Cancer Metastasis‐associated Proteins in an Isogenic Tumor Metastasis Model Using Two‐dimensional Gel Electrophoresis and Liquid Chromatography‐ion Trap‐mass Spectrometry

Label‐Free Quantitative Proteomic Screening of Candidate Plasma Biomarkers for the Prognosis of Breast Cancer with Different Lymph Node Statuses

Quantifiable peptide library bridges the gap for proteomics based biomarker discovery and validation on breast cancer

Discovery of Plasma Lipids as Potential Biomarkers Distinguishing Breast Cancer Patients from Healthy Controls

Detection and Identification of Serum Protein Peak at 6648 M/z As a Novel Indicator in Breast Cancer Based on Mass Spectrometry.